Vision. Connection. Innovation.

video of the thread

about us.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.

Pipeline

  1. Seralutinib (GB002) –
    Pulmonary Arterial Hypertension

    Inhaled PDGFR, CSF1R, c-KIT inhibitor
    Phase 1b ongoing, Phase 2 ongoing
  2. GB004 – Ulcerative Colitis

    Oral HIF-1α stabilizer
    Phase 2 ongoing
  3. GB5121 – Primary CNS Lymphoma

    Oral CNS-Penetrant BTK Inhibitor
    Phase 1 planned
  4. GB7208 – Multiple Sclerosis

    Oral CNS-Penetrant BTK Inhibitor
    Preclinical Programs
  5. Discovery Programs

    Multiple Preclinical Programs
  1. Seralutinib (GB002) –
    Pulmonary Arterial Hypertension

  2. GB004 – Ulcerative Colitis

  3. GB5121 – Primary CNS Lymphoma

*Targets to be disclosed

scroll